ν˜„λŒ€ADM 둜고

ν˜„λŒ€ADM (187660) μ£Όκ°€ 및 μ’…λͺ© 정보

ν˜„λŒ€ADM μ‹€μ‹œκ°„ μ£Όκ°€

ν˜„λŒ€ADM ν˜„μž¬κ°€ 상세 정보
ν•­λͺ© κ°’
ν˜„μž¬κ°€ 2,675 원
λ³€λ™λŸ‰ β–Ό 105.00 원
변동λ₯  -3.78%
κ±°λž˜λŸ‰ 1,203,261
κ±°λž˜λŒ€κΈˆ 3,227,499,497 원

ν˜„λŒ€ADM 일별 μ£Όκ°€

ν˜„λŒ€ADM의 κ³Όκ±° 일별 μ£Όκ°€
λ‚ μ§œ μ‹œκ°€ κ³ κ°€ μ €κ°€ μ’…κ°€ κ±°λž˜λŸ‰ κ±°λž˜λŒ€κΈˆ
11/30/2025 2,550 2,580 2,445 2,475 678,756 1,694,394,304
12/1/2025 2,505 2,895 2,440 2,765 6,121,707 16,886,603,968
12/2/2025 2,775 2,955 2,735 2,845 2,644,770 7,543,062,572
12/3/2025 3,030 3,100 2,770 2,890 3,999,192 11,797,086,623
12/4/2025 2,940 2,940 2,770 2,775 892,668 2,513,900,206
12/7/2025 3,000 3,120 2,840 2,860 4,748,470 14,184,087,363
12/8/2025 2,870 2,995 2,810 2,980 1,524,416 4,524,752,582
12/9/2025 3,200 3,205 2,750 2,805 5,577,018 16,658,232,235
12/10/2025 2,810 2,870 2,700 2,780 1,352,860 3,754,185,348
12/11/2025 2,830 2,830 2,650 2,675 1,203,261 3,227,499,497

κ΄€λ ¨ ν…Œλ§ˆ

ν˜„λŒ€ADM νšŒμ‚¬ 정보

μ‹œμž₯ μ‹œκ°€μ΄μ•‘ κΈ°μ—…μˆœμœ„ μ£Όμ‹μˆ˜ 외ꡭ인 비쀑 μ‚°μ—…κ΅° μ„ΈλΆ€ μ‚°μ—…κ΅° 52μ£Ό 졜고 52μ£Ό μ΅œμ €
kosdaq 1,446μ–΅ 620μœ„ 54,075,422 0.26% ν—¬μŠ€μΌ€μ–΄ 생λͺ…κ³Όν•™/곡학 3,795 1,118

ν˜„λŒ€ADM κΈ°μ—… κ°œμš”

μ—μ΄λ””μ— μ½”λ¦¬μ•„λŠ” 2003λ…„ 10μ›” μ„€λ¦½λœ κΈ°μ—…μœΌλ‘œ μž„μƒμ‹œν—˜ μˆ˜νƒκΈ°κ΄€μœΌλ‘œ μ œμ•½νšŒμ‚¬, λ°”μ΄μ˜€λ²€μ²˜ 등에 μž„μƒμ‹œν—˜κ³Ό κ΄€λ ¨ν•œ μ „ μ˜μ—­μ— 걸친 μ„œλΉ„μŠ€ 사업을 μ˜μœ„ν•˜κ³  μžˆλ‹€. μ£Όμš” 쒅속기업은 μ—μ΄λ””μ— λ°”μ΄μ˜€μ‚¬μ΄μ–ΈμŠ€(μ£Ό)κ°€ μžˆλ‹€. μ£Όμš” λ§€μΆœμ€ μš©μ—­ λΆ€λ¬Έμ—μ„œ λ°œμƒν•˜κ³  μžˆλ‹€. μ‹ μ•½μ˜ μ‹œνŒμ„ μœ„ν•΄μ„œλŠ” μž‘κ²ŒλŠ” 5λ…„μ—μ„œ 평균 10λ…„ λ™μ•ˆ 단계별 μž„μƒμ‹œν—˜(1상, 2상, 3상)을 μˆ˜ν–‰ν•΄μ•Ό ν•˜λ©°, λ‹Ήμ‚¬λŠ” μ΄λŸ¬ν•œ 역할을 μˆ˜ν–‰ν•˜κΈ° μœ„ν•΄ κ³ κ°μ‚¬λ‘œλΆ€ν„° μž„μƒμ‹œν—˜μ— κ΄€ν•œ 전체 λ˜λŠ” 일뢀 업무λ₯Ό μœ„νƒ λ°›μ•„ μˆ˜ν–‰ν•˜κ³  μžˆλ‹€.

ν˜„λŒ€ADM AI예츑

AIμ˜ˆμΈ‘κΈ°λŠ” ν˜„λŒ€ADM을 κ°•λ ₯맀도 Β· 맀도 Β· 쀑립 Β· 맀수 Β· κ°•λ ₯맀수 둜 μ˜ˆμΈ‘ν–ˆμ–΄μš”.

멀버십 ν”Œλžœμ„ κ΅¬λ…ν•˜λ©΄ μ˜ˆμƒ μ£Όκ°€ μ‹œλ‚˜λ¦¬μ˜€μ™€ AI의 투자의견, λͺ©ν‘œΒ·μ†μ ˆκ°€, AIκ°€ μ°Έκ³ ν•œ 차트 νŒ¨ν„΄λ“€μ„ 확인할 수 μžˆμŠ΅λ‹ˆλ‹€.

ν˜„λŒ€ADM μ§€ν‘œλΆ„μ„

수읡λ₯  1μœ„ λ§€λ§€μ „λž΅μ€ ν˜„λŒ€ADM을 맀수 Β· 맀도 Β· 보유 Β· 관망 μ€‘μ΄μ—μš”.

멀버십 ν”Œλžœμ„ κ΅¬λ…ν•˜λ©΄ 수읡λ₯  1μœ„ λ§€λ§€μ „λž΅μ˜ 맀맀 μ‹œμ μ„ ν™•μΈν•˜κ³  λ‹€μŒ μ‹ ν˜Έλ₯Ό μ•Œλ¦ΌμœΌλ‘œ λ°›μ•„λ³Ό 수 μžˆμŠ΅λ‹ˆλ‹€.

μ΅œμ‹  ν˜„λŒ€ADM κ΄€λ ¨ λ‰΄μŠ€

ν˜„λŒ€ADMλ°”μ΄μ˜€λŠ” μ‹ν’ˆμ˜μ•½ν’ˆμ•ˆμ „μ²˜λ‘œλΆ€ν„° μ‚Όμ€‘μŒμ„±μœ λ°©μ•”(TNBC) 및 λΉ„μ†Œμ„Έν¬νμ•”(NSCLC) ν™˜μžλ₯Ό λŒ€μƒμœΌλ‘œ νŽ˜λ‹ˆνŠΈλ¦¬μ›€(Penetriumβ„’)κ³Ό ν‚€νŠΈλ£¨λ‹€(μ„±λΆ„λͺ…: νŽ¨λΈŒλ‘€λ¦¬μ£Όλ§™) λ³‘μš© νˆ¬μ—¬μ˜ μ•ˆμ „μ„± 및 μ΅œλŒ€ λ‚΄μ•½ μš©λŸ‰μ„ ν‰κ°€ν•˜λŠ” μž„μƒ 1상 μ‹œν—˜κ³„νšμ„ μ΅œμ’… μŠΉμΈλ°›μ•˜λ‹€κ³  10일 λ°ν˜”λ‹€. 이번 μž„μƒμ€ μ§€λ‚œλ‹¬ λͺ¨νšŒμ‚¬μΈ ν˜„λŒ€λ°”μ΄μ˜€κ°€ μ΅œμ’… νšλ“ν•œ 전립선암에 λŒ€ν•œ μž„μƒμŠΉμΈκ³Ό ν•¨κ»˜ κΈ°μ‘΄ ν•­μ•” 치료 μ‹€νŒ¨μ˜ μ›μΈμœΌλ‘œ 지적돼 온 ν˜„μƒμ„ 'κ°€μ§œλ‚΄μ„±'(pseudo-resistance)μ΄λΌλŠ” μƒˆλ‘œμš΄ 병리 κΈ°μ „μ˜ 극볡을 μΈμ²΄λ‚΄μ—μ„œ ν™•μΈν•˜λŠ” 과정이닀. 'κ°€μ§œλ‚΄μ„±'은 ν•­μ•” 치료 κ³Όμ •μ—μ„œ λ‚˜νƒ€λ‚˜λŠ” 치료 λ°˜μ‘ μ €ν•˜λ₯Ό μ•”μ„Έν¬μ˜ μœ μ „μž λ³€μ΄λ‚˜ μ•½λ¬Ό λ‚΄μ„±λ§ŒμœΌλ‘œ μ„€λͺ…ν•˜λŠ” 데 ν•œκ³„κ°€ μžˆλ‹€λŠ” λ¬Έμ œμ˜μ‹μ—μ„œ μΆœλ°œν•œ κ°œλ…μ΄λ‹€. ν•­μ•”μ œ 반볡 νˆ¬μ—¬ κ³Όμ •μ—μ„œ 암쑰직 μ£Όλ³€μ˜ μ„Έν¬μ™ΈκΈ°μ§ˆ(ECM)이 λ‘κΊΌμ›Œμ§€κ³  κ²½μ§λ˜λ©΄μ„œ ν•­μ•”μ œκ°€ 암쑰직 λ‚΄λΆ€λ‘œ λ„λ‹¬ν•˜κΈ° μ–΄λ €μš΄ ν™˜κ²½μ΄ ν˜•μ„±λœλ‹€λŠ” 병리 기전에 μ£Όλͺ©ν•œλ‹€....

[λ°μΌλ¦¬ν•œκ΅­ 민병무 기자] ν˜„λŒ€ADMλ°”μ΄μ˜€λŠ” μ‹ν’ˆμ˜μ•½ν’ˆμ•ˆμ „μ²˜λ‘œλΆ€ν„° μ‚Όμ€‘μŒμ„±μœ λ°©μ•”(TNBC) 및 λΉ„μ†Œμ„Έν¬νμ•”(NSCLC) ν™˜μžλ₯Ό λŒ€μƒμœΌλ‘œ νŽ˜λ‹ˆνŠΈλ¦¬μ›€(Penetrium)κ³Ό ν‚€νŠΈλ£¨λ‹€(μ„±λΆ„λͺ…: νŽ¨λΈŒλ‘€λ¦¬μ£Όλ§™) λ³‘μš© νˆ¬μ—¬μ˜ μ•ˆμ „μ„± 및 μ΅œλŒ€ λ‚΄μ•½ μš©λŸ‰μ„ ν‰κ°€ν•˜λŠ” μž„μƒ 1상 μ‹œν—˜κ³„νšμ„ μ΅œμ’… μŠΉμΈλ°›μ•˜λ‹€κ³  10일 λ°ν˜”λ‹€.이번 μž„μƒμ€ μ§€λ‚œλ‹¬ λͺ¨νšŒμ‚¬μΈ ν˜„λŒ€λ°”μ΄μ˜€κ°€ μ΅œμ’… νšλ“ν•œ 전립선암에 λŒ€ν•œ μž„μƒμŠΉμΈκ³Ό ν•¨κ»˜ κΈ°μ‘΄ ν•­μ•” 치료 μ‹€νŒ¨μ˜ μ›μΈμœΌλ‘œ 지적돼 온 ν˜„μƒμ„ β€˜κ°€μ§œλ‚΄μ„±(pseudo-resistance)β€™μ΄λΌλŠ” μƒˆλ‘œμš΄ 병리 κΈ°μ „μ˜ 극볡을 인체 λ‚΄μ—μ„œ 확인할

[μΈν¬μŠ€νƒλ°μΌλ¦¬=박상철 기자]μΈν¬μŠ€νƒλ°μΌλ¦¬κ°€ 맀일 μ•„μΉ¨ μ „ 세계 투자 정보λ₯Ό 담은 λ‰΄μŠ€λ₯Ό λ°°λ‹¬ν•΄λ“œλ¦½λ‹ˆλ‹€. λ―Έκ΅­μ¦μ‹œ 마감과 μ‹œμž₯ 이슈, μ£Όλͺ©ν• λ§Œν•œ μΈμ‚¬μ΄νŠΈκ°€ λ‹΄κΈ΄ μ£Όμš” μ™Έμ‹ , κ΅­λ‚΄ μ‹œμž₯ μ’…λͺ©λ“€μ˜ μ‹œμ„Έλ₯Ό 움직일 λ‰΄μŠ€ 등을 μ—„μ„ ν–ˆμŠ΅λ‹ˆλ‹€. μ¦μ‹œ 개μž₯ μ „ λΉ λ₯΄κ²Œ λ³€ν•˜λŠ” μ‹œμž₯ ν˜„ν™©μ„ μ‚΄νŽ΄λ³΄κ³  이λ₯Ό 톡해 νˆ¬μžμ „λž΅μ„ 점검할 수 μžˆλ„λ‘ 마련된 μ½”λ„ˆμž…λ‹ˆλ‹€.β–  κ΅­λ‚΄μ¦μ‹œμ½”μŠ€ν”Ό μ§€μˆ˜λŠ” 1.78% μƒμŠΉν•œ 4100.05에 λ§ˆκ°ν–ˆλ‹€.μˆ˜κΈ‰λ³„λ‘œλŠ” 외ꡭ인과 기관이 각각 1μ‘°9μ–΅, 1μ‘°1529μ–΅ 순맀수, κ°œμΈμ€ 2μ‘°1156μ–΅ μˆœλ§€λ„ν–ˆλ‹€. μ„ λ¬Όμ‹œμž₯μ—μ„œλŠ” 외ꡭ인이 582

[μΈν¬μŠ€νƒλ°μΌλ¦¬=박상철 기자]β–  美 FOMC μ˜μ‚¬λ‘ 곡개 - ν˜„μ§€μ‹œκ°„ 19일(ν•œκ΅­μ‹œκ°„ 20일 μ˜€μ „ 4μ‹œ) λ―Έκ΅­ μ—°λ°©κ³΅κ°œμ‹œμž₯μœ„μ›νšŒ(FOMC)의 10μ›” μ˜μ‚¬λ‘μ΄ 곡개될 μ˜ˆμ •μ΄λ‹€.β–  美 μ—”λΉ„λ””μ•„ μ‹€μ λ°œν‘œ - ν˜„μ§€μ‹œκ°„ 19일(ν•œκ΅­μ‹œκ°„ 20일 μ˜€μ „ 7μ‹œ) 컴퓨터 κ·Έλž˜ν”½μš© μΉ© μ œμ‘°μ—…μ²΄μΈ μ—”λΉ„λ””μ•„(NVIDIA)κ°€ 3λΆ„κΈ° 싀적을 λ°œν‘œν•œλ‹€. κ΄€λ ¨ μ„Ήν„°λ‘œλŠ” λ°˜λ„μ²΄ λŒ€ν‘œμ£Ό(생산), λ°˜λ„μ²΄ μž₯λΉ„, λ°˜λ„μ²΄ 재료/λΆ€ν’ˆ, μ‹œμŠ€ν…œλ°˜λ„μ²΄, IT λŒ€ν‘œμ£Ό, HBM(κ³ λŒ€μ—­ν­λ©”λͺ¨λ¦¬)이 μžˆλ‹€.β–  μ‘΄ μœŒλ¦¬μ—„μŠ€ λ‰΄μš• 연은 총재 μ—°μ„€ - ν˜„μ§€μ‹œκ°„ 19일 μ‘΄ μœŒλ¦¬μ—„μŠ€ λ‰΄μš• μ—°λ°©

ν˜„λŒ€ADM은 μž„μƒ μ „λ¬ΈκΈ°κ΄€ ν”„λ¦¬ν΄λ¦¬λ‚˜μ—κ²Œ μ•žμ„œ μ§„ν–‰ν•œ λΉ„μž„μƒ μ •λ°€ 뢄석 의뒰결과 κΈ°μ‘΄ λ©΄μ—­μ–΅μ œ μΉ˜λ£Œμ™€ 달리 λ₯˜λ§ˆν‹°μŠ€ κ΄€μ ˆμ—Όμ˜ 근본적 원인인 '병리적 쑰직'을 μ •μƒν™”μ‹œν‚¨ κ²ƒμœΌλ‘œ λ³΄μ΄λŠ” 데이터λ₯Ό ν™•μΈν–ˆλ‹€κ³  14일 λ°ν˜”λ‹€. νšŒμ‚¬λŠ” μ•žμ„œ μ§„ν–‰ν•œ λΉ„μž„μƒμ‹œν—˜ λŒ€μƒ 각ꡰ별 μ₯λ“€μ— λŒ€ν•œ μ •λ°€ν•œ 쑰직뢄석을 μ˜λ’°ν•΄ 이 같은 κ²°κ³Όλ₯Ό μ–»μ—ˆλ‹€κ³  μ„€λͺ…ν–ˆλ‹€. 쑰직뢄석 결과에 λ”°λ₯΄λ©΄ λŒ€μ‘°κ΅°(무처치ꡰ)은 병리적 쑰직(pannus)이 ν˜•μ„±λ˜μ–΄ '연골-골 경계'κ°€ λΆ•κ΄΄λμœΌλ©° 염증세포도 κ΄‘λ²”μœ„ν•˜κ²Œ μ‘΄μž¬ν•œ κ²ƒμœΌλ‘œ ν™•μΈν–ˆλ‹€. ν˜„μž¬ ν‘œμ€€ 치료제인 MTX νˆ¬μ—¬κ΅°μ—μ„œλŠ” 염증 μ–΅μ œλŠ” μ΄λ£¨μ–΄μ‘Œμ§€λ§Œ 병리적 쑰직은 μ—¬μ „νžˆ μœ μ§€λλ‹€. 반면 ν˜„λŒ€ADM의 νŽ˜λ‹ˆνŠΈλ¦¬μ›€(Penetrium) 단독 νˆ¬μ—¬κ΅°μ€ 병리적 쑰직이 91% 이상 μ€„μ–΄λ“€μ—ˆκ³  이둜 인해 염증도 ν˜„μ €νžˆ κ°μ†Œν•œ κ²ƒμœΌλ‘œ λ‚˜νƒ€λ‚¬λ‹€. νŽ˜λ‹ˆνŠΈλ¦¬μ›€κ³Ό κΈ°μ‘΄ 치료제인 MTXλ₯Ό ν•¨κ»˜ νˆ¬μ•½ν•œ λ³‘μš©κ΅°μ€ 병리적 쑰직이 98% 이상 μ€„μ—ˆκ³  염증도 사라져 μ™„μ „κ΄€ν•΄ μˆ˜μ€€μ˜ 쑰직 정상화λ₯Ό κ΄€μ°°ν–ˆλ‹€. ν˜„λŒ€AD...

ν˜„λŒ€ADM 맀좜 정보

λ‚ μ§œ λ§€μΆœμ•‘ λ§€μΆœμ•‘ μ¦κ°€μœ¨ μ˜μ—…μ΄μ΅ μ˜μ—…μ΄μ΅ μ¦κ°€μœ¨ 순이읡 순이읡 μ¦κ°€μœ¨
2024.4Q 9,744,986,676 -29.33% -15,932,446,161 -359.86% -20,260,475,756 -502.40%
2023.4Q 13,790,195,699 -7.34% -3,464,613,885 -359.05% -3,363,294,388 -5611.85%
2022.4Q 14,882,556,000 6.47% -754,740,500 -136.10% -58,882,744 -103.41%
2021.4Q 13,977,772,000 - 2,090,550,500 - 1,726,994,300 -

μˆœλ§€μˆ˜λŸ‰

개인: 30,879

κΈ°κ΄€: 0

외인: -36,586

λˆ„μ  μˆœλ§€μˆ˜λŸ‰

개인: 3,012,460

κΈ°κ΄€: -1,604,636

외인: -781,514

순맀수

λ‚ μ§œ 개인 κΈ°κ΄€ 외인
2025-12-12 30,879 - -36,586
2025-12-11 -32,061 - 41,562
2025-12-10 361,326 - -376,537
2025-12-09 -23,497 - 23,497
2025-12-08 -177,153 - 183,247
2025-12-05 35,203 - -40,040
2025-12-04 328,729 - -309,637
2025-12-03 -174,870 - 197,933
2025-12-02 30,080 - 28,530
2025-12-01 78,281 - -67,278
2025-11-28 2,835 - 165
2025-11-27 112,732 - -107,732
2025-11-26 9,151 - -4,151
2025-11-25 -20,593 - 54,277
2025-11-24 -52,600 - 88,851
2025-11-21 -12,441 - 42,971
2025-11-20 74,696 - -36,743
2025-11-19 -107,141 - 126,949
2025-11-18 -26,918 - 28,576
2025-11-17 -68,237 - 68,237
2025-11-14 174,645 - -196,683

λˆ„μ  순맀수

λ‚ μ§œ 개인 κΈ°κ΄€ 외인
2025-12-12 543,046 - -290,592
2025-12-11 512,167 - -254,006
2025-12-10 544,228 - -295,568
2025-12-09 182,902 - 80,969
2025-12-08 206,399 - 57,472
2025-12-05 383,552 - -125,775
2025-12-04 348,349 - -85,735
2025-12-03 19,620 - 223,902
2025-12-02 194,490 - 25,969
2025-12-01 164,410 - -2,561
2025-11-28 86,129 - 64,717
2025-11-27 83,294 - 64,552
2025-11-26 -29,438 - 172,284
2025-11-25 -38,589 - 176,435
2025-11-24 -17,996 - 122,158
2025-11-21 34,604 - 33,307
2025-11-20 47,045 - -9,664
2025-11-19 -27,651 - 27,079
2025-11-18 79,490 - -99,870
2025-11-17 106,408 - -128,446
2025-11-14 174,645 - -196,683

ν˜„λŒ€ADM μžμ‚° λΉ„μœ¨

μžμ‚°μ΄κ³„ λΆ€μ±„λΉ„μœ¨ μžλ³ΈλΉ„μœ¨
25,538,658,728 57.96% 42.04%

ν˜„λŒ€ADM 맀좜 ꡬ성

ꡬ성 μš”μ†Œ λΉ„μœ¨
Clinical trial [μš©μ—­] 64.9%
LPS [μš©μ—­] 32.9%
μž„λŒ€ 1.9%
μƒν’ˆ [μž¬ν™”μ˜] 0.3%

ν˜„λŒ€ADM 곡맀도 ν˜„ν™©

졜근 곡맀도 κ±°λž˜λŸ‰: 46,222 (3.84%)

졜근 곡맀도 μž”κ³ : 552,927 (1.02%)

곡맀도 κ±°λž˜λŸ‰

λ‚ μ§œ μ’…κ°€ κ³΅λ§€λ„λŸ‰ 곡맀도비쀑
2025-12-12 2,675 46,222 3.84%
2025-12-11 2,780 0 0.00%
2025-12-10 2,805 18,838 0.34%
2025-12-09 2,980 51,242 3.36%
2025-12-08 2,860 9,854 0.21%
2025-12-05 2,775 34,308 3.84%
2025-12-04 2,890 1,437 0.04%
2025-12-03 2,845 2,300 0.09%
2025-12-02 2,765 6,627 0.11%
2025-12-01 2,475 13,156 1.94%
2025-11-28 2,465 103 0.02%
2025-11-27 2,420 114 0.02%
2025-11-26 2,445 0 0.00%
2025-11-25 2,415 0 0.00%
2025-11-24 2,440 0 0.00%
2025-11-21 2,465 0 0.00%
2025-11-20 2,570 0 0.00%
2025-11-19 2,625 0 0.00%
2025-11-18 2,695 0 0.00%
2025-11-17 2,920 325 0.03%
2025-11-14 2,970 32 0.00%

곡맀도 μž”κ³ 

λ‚ μ§œ μ’…κ°€ 곡맀도 μž”κ³  곡맀도 비쀑
2025-12-10 2,805 552,927 1.02%
2025-12-09 2,980 349,147 0.65%
2025-12-08 2,860 346,314 0.64%
2025-12-05 2,775 453,802 0.84%
2025-12-04 2,890 427,676 0.79%
2025-12-03 2,845 415,682 0.77%
2025-12-02 2,765 394,668 0.73%
2025-12-01 2,475 360,870 0.67%
2025-11-28 2,465 362,260 0.67%
2025-11-27 2,420 383,783 0.71%
2025-11-26 2,445 346,292 0.64%
2025-11-25 2,415 317,684 0.59%
2025-11-24 2,440 290,843 0.54%
2025-11-21 2,465 354,637 0.66%
2025-11-20 2,570 295,172 0.55%
2025-11-19 2,625 312,205 0.58%
2025-11-18 2,695 371,553 0.70%
2025-11-17 2,920 373,705 0.71%
2025-11-14 2,970 389,447 0.74%
2025-11-13 2,945 259,568 0.49%
2025-11-12 2,840 353,358 0.67%

ν˜„λŒ€ADM μ—…μ’… λ‚΄ 비ꡐ

생λͺ…κ³Όν•™/곡학 μ—…μ’…(90개) μ—°κ°„ κΈ°μ€€

ν•­λͺ© ν˜„λŒ€ADM μ—…μ’… 평균 μ—…μ’… λ‚΄ μˆœμœ„
μ‹œκ°€μ΄μ•‘ 1,503.297 11,105.7 47μœ„
PER(졜근4λΆ„κΈ°) -9.631 -173.83 55μœ„
PBR 12.962 26.49 23μœ„
ROE(졜근4λΆ„κΈ°) -118.306 -33.48 83μœ„
λ°°λ‹Ήμˆ˜μ΅λ₯ (μ΅œκ·Όμ—°λ„) - - -μœ„
μ˜μ—…μ΄μ΅λ₯ (μ΅œκ·Όμ—°λ„) -163.494 -1,637.76 46μœ„
순이읡λ₯ (μ΅œκ·Όμ—°λ„) -207.907 -1,546.74 54μœ„
λΆ€μ±„λΉ„μœ¨(μ΅œκ·Όμ—°λ„) 330.363 77.86 2μœ„
λ§€μΆœμ•‘(μ΅œκ·Όμ—°λ„) 97.45 490.15 40μœ„
μ˜μ—…μ΄μ΅(μ΅œκ·Όμ—°λ„) -159.324 -86.02 64μœ„
λ‹ΉκΈ°μˆœμ΄μ΅(μ΅œκ·Όμ—°λ„) -202.605 -64.08 71μœ„